Bexson Biomedical is developing differentiated therapies using precision-driven, scalable delivery technologies for pain and mental health
Bexson Biomedical is developing differentiated therapies using precision-driven, scalable delivery technologies for pain and mental health. Their lead candidate, BB106, is an IND-ready subcutaneous ketamine derivative in development for Moderate/Severe Acute Pain.